Biotechnology company building liver health and wellness products
Raised to date
$8M
of $12M offered across 1 Form D filing
It positions its work as replacing symptom-masking supplements with mechanistic, human-proven interventions engineered through computational biology. Its stated roadmap starts with alcohol clearance, expands to resilience during medication use, and ultimately targets liver longevity. The company is headquartered in Lewes, Delaware and was founded in 2025.
Uses computational biology to design mechanistic, human-proven liver interventions rather than conventional symptom-masking supplements.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Mar 23, 2026 | Equity | $8M/ $12M | Form D |
Liver wellness product
An on-demand elixir the company says dramatically accelerates alcohol clearance while protecting the liver.
Built for
Consumers seeking liver health and longevity products, starting with people who drink alcohol